Skip to main content

Table 1 Patient data

From: Polypharmacy in patients with multiple sclerosis: a gender-specific analysis

  Women, N (%) Men, N (%) p value
N 218 88  
Sociodemographic data
 Age (years) 19–86R 48.3 (13.7)a 24–78R 49.6 (11.4)a 0.375t
  ≤ 29 20 (9.2) 3 (3.4)
  30–39 46 (21.1) 18 (20.5)
  40–49 42 (19.3) 22 (25.0)
  50–59 66 (30.3) 30 (34.1)
  ≥ 60 44 (20.2) 15 (17.0)
 School years 6–16R 10b 8–13R 10b 0.386U
 Educational level    0.531Chi
  No training 5 (2.3) 1 (1.1)
  Skilled worker 151 (69.3) 55 (62.5)
  Technical college 13 (6.0) 6 (6.8)
  University 49 (22.5) 26 (29.5)
 Employment status    0.092Chi
  In training 5 (2.3) 1 (1.1)
  Employed 73 (33.5) 42 (47.7)
  Unemployed 8 (3.7) 2 (2.3)
  Retiree 125 (57.3) 43 (48.9)
  Others 7 (3.2) 0 (0.0)
 Partnership    0.888Fi
  Yes 159 (72.9) 63 (71.6)
  No 59 (27.1) 25 (28.4)
 Place of residence    0.125Chi
  Rural community 68 (31.2) 17 (19.3)
  Provincial town 42 (19.3) 15 (17.0)
  Medium-sized town 29 (13.3) 14 (15.9)
  City 79 (36.2) 42 (47.7)
 Number of children 0–4R 1b 0–4R 1b 0.088U
  0 56 (25.7) 25 (28.4)
  1 57 (26.1) 30 (34.1)
  ≥ 2 105 (48.2) 33 (37.5)
 Number of siblings 0–13R 1b 0–7R 1b 0.649U
  0 27 (12.4) 13 (14.8)
  1 105 (48.2) 42 (47.7)
  ≥ 2 86 (39.4) 33 (37.5)
Clinical data
 EDSS 1.0–9.0R 3.5b 1.0–9.0R 3.5b 0.471U
 Disease duration (years) 0–50R 11.0b 0–41R 11.5b 0.872U
  0*–5 68 (31.2) 20 (22.7)  
  6–10 36 (16.5) 21 (23.9)  
  11–15 35 (16.1) 19 (21.6)  
  16–20 37 (17.0) 15 (17.0)  
  ≥ 21 42 (19.3) 13 (14.8)  
 Disease course    0.041 Chi
  CIS/RRMS 140 (64.2) 52 (59.1)  
  SPMS 60 (27.5) 20 (22.7)  
  PPMS 18 (8.3) 16 (18.2)  
 Comorbidities    0.237Fi
  Pw/oSI 73 (33.5) 36 (40.9)  
  PwSI 145 (66.5) 52 (59.1)  
 Patient care    0.527Fi
  Outpatients 107 (49.1) 39 (44.3)  
  Inpatients 111 (50.9) 49 (55.7)  
Pharmacological data
 Polypharmacy 122 (56.0) 51 (58.0) 0.799Fi
 All medicationsc 5.8 (3.7) 5.3 (3.1) 0.443U
 Long-term medicationsc 4.6 (3.4) 4.1 (2.8) 0.353U
 PRN drugsc 1.2 (1.4) 1.2 (1.3) 0.972U
 Prescription-only drugsc 4.7 (3.4) 4.2 (2.6) 0.618U
 OTC drugsc 1.2 (1.3) 1.1 (1.2) 0.730U
 DMDc 1.0 (0.3) 0.9 (0.3) 0.437U
 Symptomatic drugsc 1.9 (1.9) 2.1 (1.9) 0.212U
 Comorbidity drugsc 3.0 (2.7) 2.3 (2.1) 0.021 U
  1. CIS clinically isolated syndrome, DMD disease-modifying drug, EDSS expanded disability status scale, MS multiple sclerosis, N number of patients, PPMS primary progressive MS, PwSI patients with secondary illnesses, Pw/oSI patients without secondary illnesses, RRMS relapsing-remitting MS, SPMS secondary progressive MS
  2. *Six weeks as the lowest disease duration
  3. aMean value (standard deviation)
  4. bMedian
  5. cMean (standard deviation) number of drugs taken per patient
  6. ChiChi-square test
  7. FiFisher’s exact test
  8. RRange
  9. tTwo-sample two-tailed Student’s t test
  10. UMann-Whitney U test